Sinsin Pharmaceutical Co Ltd

Sinsin Pharmaceutical Co Ltd maintains a debt-to-equity ratio of 0.58, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.98, suggesting that its current liabilities slightly exceed its current assets. Free cash flow stands at 10,819.71 million KRW, supporting operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 12.42% and a return on assets (ROA) of 6.76%, both of which are strong indicators of efficient capital utilization and asset management. These figures suggest that the company is generating solid returns for shareholders and effectively deploying its assets. The company's revenue is concentrated in a single business segment focused on OTC drug products, with no disclosed geographic diversification beyond its primary operations in Korea. This concentration may expose the company to regional economic or regulatory risks. Outlook data indicates a positive growth trajectory, with revenue expected to increase in the current fiscal year. Historical revenue growth and the company's strong cash flow generation support this optimistic outlook. However, the absence of detailed segment or geographic growth projections limits visibility into specific drivers of future performance. Risk factors include a medium liquidity risk due to the current ratio being below 1 and a negative net cash position after accounting for total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. Recent events include the disclosure of a last actual EPS of 24.00 KRW, reflecting the company's earnings performance. No recent filings or transcripts have been provided that indicate material changes in the company's strategic direction or financial health.